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ABSTRACT 
Objective: Development and validation of quantitative simultaneous determination of aliskiren hemifumarate (ALI) and hydrochlorothiazide (HCT) 
in combined tablet formulation by RP-HPLC. 
Methods: The separation of components were achieved on Enable C18 
Results: Linear concentration range was between 1.2-240 µg/ml for ALI and 0.1-20 µg/ml for HCT and correlation coefficient was found to be 
0.9995 and 0.9998, respectively. The limit of detection and limit of quantification for ALI was found to be 0.3376 and 1.0230 µg/ml and for HCT 
0.0288 and 0.0873 µg/ml, respectively. The results of precision (% RSD<2) studies showed good reproducibility. Recovery study was performed at 
50, 100 and 150 % level to check the interferences between analytes and formulation excipients and % recovery was found to be 99.49±0.9868 for 
ALI and 99.87±0.8556 for HCT. The percentage assay was found to be 100.36±0.9201 and 99.40±0.7624 for ALI and HCT, respectively. 
column (250×4.6 mm, 5 µm) with a mobile phase consisting of 0.2 %v/v 
triethylamine in water (pH 6 was adjusted with orthophosphoric acid): methanol (10:90 %v/v) at a flow rate of 1 ml/min was employed. 
Quantification was achieved with PDA detection at 280 nm. Validation parameters of the proposed method such as specificity, linearity, accuracy, 
precision and robustness were evaluated according to ICH guidelines. 
Conclusion: A simple, rapid, cost effective and highly sensitive RP-HPLC method as compared to existing methods for the determination of ALI and 
HCT in tablet formulation was developed and validated as per ICH guidelines. The method uses simple reagents and sample preparation procedures 
were minimal. Thus, the proposed method can be applied for routine quality control determination of ALI and HCT in tablet formulation. 
Keywords: Aliskiren hemifumarate, Hydrochlorothiazide, RP-HPLC, Tablet formulation. 
 
INTRODUCTION 
Aliskiren hemifumarate (ALI) is chemically described as (2S,4S,5S,7S)-N-
(2-methylpropyl) 5amino-4-hydroxy-2,7diisopropyl-8-[4-methoxy-3-(3-
methoxypropoxy)phenyl]-octamide hemifumarate, a rennin inhibitor 
used for the treatment of essential hypertension. Hydrochlorothiazide 
(HCT), chemically 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-
sulfomide 1,1-dioxide is a thiazide diuretic used in the management of 
hypertension. Chemical structures of both the drugs are shown in fig. 1. 
 
 
Fig. 1: Chemical structures of ALI (aliskiren hemifumarate) and 
HCT (hydrochlorothiazide) 
 
Hypertension is one of the most common and powerful risk factors 
for cardiovascular diseases. Blood pressure control is pre requisite 
for the management of cardiovascular diseases and complications. 
More than one medication is required for effective control of blood 
pressure of the cardiovascular patients. ALI is the first 
representative of a new class of non peptide, low molecular weight; 
orally active transition state rennin inhibitor shows the effective 
control of blood pressure and cardiovascular diseases when 
combined with HCT, a thiazide diuretic [1-3].  
Literature survey revealed various analytical methods for the 
determination of ALI along with HCT in their pharmaceutical 
formulation using HPLC [4-15], HPTLC [16-18], spectrophotometry 
[19] and electrophoresis [20]. Still there was need for a more 
sensitive method for the determination of ALI and HCT in their 
tablet dosage form which can cover up the lacuna of some existing 
methods. Therefore, aim of the present work was to develop and 
validate a simpler, sensitive, precise, accurate and cost effective RP-
HPLC method compared to existing methods for the determination 
of ALI and HCT in tablet formulation. The advantages of proposed 
method are as follows; separation was achieved using C18 column 
(most widely used), 0.2% triethylamine in water (pH 6 with 
orthophosphoric acid) and methanol as mobile phase, which can be 
afforded by all the laboratories; fumaric acid was well separated 
from both the analytes; method describes standard and sample 
preparation procedure based on the form of analytes under 
investigation, i.e. aliskiren (13.26 mg of aliskiren hemifumarate is 
equivalent to 12 mg of aliskiren); wide concentration range with 
high sensitivity. Moreover, the method can be used for the analysis 
of ALI and HCT in biological fluids or in pharmacokinetics studies. 
MATERIALS AND METHODS 
Chemicals and reagents 
ALI hemifumarate reference standard was provided by Jubilant Life 
Sciences Ltd., Noida, Uttar Pradesh, India and HCT was obtained 
from Glenmark Pharmaceuticals Ltd., Mumbai, Maharashtra, India. 
Rasilez HCT tablets containing 300 mg of ALI along with 25 mg of 
HCT were purchased from commercial sources. Methanol and 
triethylamine used were of HPLC grade and purchased from Merck 
Specialities Private Limited, Mumbai, India and Loba Chemie Pvt. 
Ltd., Mumbai, India. HPLC grade water was used for all the analyses 
(Millipore Direct Q3, Millipore India, Bangalore, India). 
Apparatus and chromatographic condition 
Shimadzu UFLC Prominence (Shimadzu, Kyoto, Japan) equipped 
with LC-20AD binary pump, SPD-M20A PDA detector and LC 
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solution as software was used for the analysis. Separation was 
achieved on Enable C18 column (250×4.6 mm i.d., 5 µm particle size, 
120 Å). To protect the analytical column a guard column (C18
Preparation of standard solution 
, 120 Å) 
was used. Isocratic Shimadzu LC system was operated at 25 °C using 
a mobile phase consisting of 0.2% triethylamine in water (pH 6 was 
adjusted using 5 %v/v orthophosphoric acid) and methanol (10:90 
%v/v) at a flow rate of 1 ml/min and eluents were monitored at 280 
nm using PDA detector with 20 µl injection volume. 
The stock solution of HCT was prepared by weighing accurately 10 
mg of HCT standard drug which was then transferred to a 10 ml 
volumetric flask and diluted to 10 ml with mobile phase to get the 
concentration of the drug 1000 µg/ml. The mixed standard stock 
solution of ALI and HCT was prepared by weighing accurately, 13.26 
mg (13.26 mg of aliskiren hemifumarate is equivalent to 12 mg of 
aliskiren) of ALI was mixed with 1 ml of HCT standard solution 
(1000 µg/ml) in to a 10 ml volumetric flask and diluted to 10 ml 
with mobile phase to get the concentration of the drugs 1200 and 
100 µg/ml, respectively. 
Preparation of sample solution 
Twenty tablets of Rasilez HCT (300 mg of ALI and 25 mg of HCT) 
were accurately weighed and average weight was calculated. All the 
tablets were crushed to fine powder and quantity equivalent to 60 
mg of ALI and 5 mg of HCT were weighed and transferred to a 50 ml 
volumetric flask. Flasks was vortexed after adding 30 ml of mobile 
phase and shaken for 10 minutes and volume was made up to the 
mark with the mobile phase. Contents were filtered through 0.45 µm 
membrane filter and suitable aliquots were prepared to get desired 
concentrations (ALI 120 µg/ml and HCT 10 µg/ml). 
Validation of chromatographic method 
Analytical method development and validation plays a major role in 
the different stages of discovery, development and manufacturing of 
pharmaceuticals. The developed method was validated in 
accordance with the International Conference on Harmonization 
[21] guidelines for validation of analytical procedures. 
Specificity 
In order to determine the specificity of the method, a placebo solution 
(in-house mixture of all the tablet excipients) was prepared as described 
in the Handbook of Pharmaceutical Excipients and was analyzed to 
evaluate the interference among excipients and drugs peak.  
Linearity and range 
Linearity and range of the method was checked by analyzing mixed 
standard solutions containing ALI (1.2, 6, 12, 60, 120, 180 and 240 
µg/ml) and HCT (0.1, 0.5, 1, 5, 10, 15 and 20 µg/ml) were prepared 
in mobile phase. Column was equilibrated for 15 minutes with the 
mobile phase before injecting the solutions. Calibration graphs were 
plotted using peak areas of standard drugs vs concentration. Results 
were subjected to regression analysis by the least squares method to 
calculate the values of slope, intercept and correlation coefficient.  
Precision 
The precision of the method was checked by carrying out 
repeatability, intra-day and inter-day precision. To check the 
repeatability of the method a standard mixed solution was injected 6 
times and %RSD was calculated. Intra-day precision was carried out 
by analyzing three replicate injections at two different concentration 
levels on the same day within the linearity range. Inter-day precision 
was studied by comparing the results on two different days 
analyzing three replicate injections at three different concentration 
levels within the linearity range. 
Accuracy 
Recovery studies were carried out by the addition of standard drug 
to pre-analyzed sample solution at three different levels: 50, 100 
and 150% to check the accuracy of the method. The resulting 
solutions were reanalyzed and % recovery was calculated. The 
result of the accuracy study was assessed based on the percentage of 
standard ALI and HCT recovered from the formulation. 
LOD and LOQ 
The limit of detection and limit of quantification of ALI and HCT was 
calculated using the following equation as per ICH guidelines. 








Where 5  = the standard deviation of the response, S = the slope of 
the calibration curve. 
Robustness 
The robustness of an analytical procedure is refers to its ability to remain 
unaffected by small and deliberate variations in the method parameters. 
The method should be robust enough with respect to all critical 
parameters so as to allow routine laboratory use. Robustness of the 
method was checked on the basis of slight alteration in the wave length 
of detection (±2 nm), mobile phase composition (±2 %), flow rate (±0.1 
ml/min), buffer pH (±0.5 units) and buffer strength (± 0.1%). 
Stability of the solution 
Stability of the solutions were checked by observing any changes in 
the chromatographic pattern compared with freshly prepared 
solutions by keeping the solutions at room temperature and 
analyzing at a frequent interval. 
System suitability test 
System suitability tests were performed to confirm that the 
instrument was in appropriate condition for the analysis to be 
performed. Six replicates of the standard solution was injected and 
chromatograms were recorded to confirm the suitability of the 
chromatograph.  
RESULTS AND DISCUSSION 
The objective of the present study was to develop and validate a 
simple, sensitive and cost effective RP-HPLC method for 
simultaneous estimation of ALI and HCT in tablet dosage form. 
Moreover, the other objective of the developed chromatographic 
method was to obtain better resolution between ALI, HCT and FA 
(fumaric acid). The chromatographic conditions were optimized to 
achieve the best resolution and peak shape for both the drugs. The 
separation of components were achieved on Enable C18
 
 column with 
a mobile phase consisting of 0.2% triethylamine in water (pH 6 was 
adjusted with orthophosphoric acid) and methanol (10:90 %v/v) at 
a flow rate of 1 ml/min was employed with PDA detection at 280 
nm. The retention time of ALI and HCT was found to be 5.315±0.0264 
and 2.824±0.0027 min, respectively, are shown in fig. 2.  
 
Fig. 2: RP-HPLC chromatogram of ALI (120 µg/ml) and HCT (10 
µg/ml) 
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No interfering peaks were found within the stipulated run time. The 
developed method was validated as per ICH guidelines. Linearity of the 
method was established by plotting standard calibration curves between 
peak area vs concentration. ALI and HCT were found to be linear in the 
concentration range of 1.2-240 µg/ml and 0.1-20 µg/ml, respectively. As 
both the analytes under investigation obeys beer’s law in a wide 
concentration range, developed method can be applied for formulation 
as well as bio-analysis. Results were subjected to regression analysis by 
the least squares method to calculate the values of slope, intercept and 
correlation coefficient. Results of precision studies expressed in % RSD 
follows ICH guideline acceptable limits, which indicates good 
repeatability and low inter-day variability, indicating an excellent 
precision of the developed method. The results of recovery studies 
ranged from 98-101 % for both the drugs showing the accuracy of the 
method. This indicates that there is no interference from tablet 
excipients. The values of LOD and LOQ were found to be 0.3376 and 
1.0230 µg/ml for ALI, 0.0288 and 0.0873 µg/ml for HCT, respectively 
(table 1), proves the sensitivity of the developed method. 
  
Table 1: Summary of validation parameters for the proposed method 
Parameters ALI HCT 
Linearity range (µg/ml) 1.2-240 0.1-20 
Correlation coefficient 0.9995 0.9998 
Regression equation y = 5276x+1763 y = 64274x+4229 
Precision (%RSD) 




















Specificity No interference 
LOD (µg/ml) 0.3376 0.0288 
LOQ (µg/ml) 1.0230 0.0873 
n = Number of determination, *SD=Standard deviation 
 
The proposed method was checked through all the parameters 
described earlier under robustness studies, but no significant 
changes found in retention time, peak area or symmetry of the 
peaks. Solution stability was performed at room temperature and it 
was found to be stable up to two days. System suitability tests were 
performed and the results shows that the parameters tested were 
within the acceptable range (%RSD<2) and are presented in table 2, 
which suggests that the method is suitable for an intended use.  
 
Table 2: System suitability parameters 
Drugs Retention time* 
(% RSD˂ 2)** 
Peak area reproducibility* 
(% RSD˂ 2)** 














4.403±0.0549* 3552±43.58* 0.847±0.0099* 
*±SD (n=6), **%RSD 
 
The proposed method was successfully used for the quantitative 
determination of ALI and HCT in commercial formulation (Rasilez 
HCT tablet: 300 mg of ALI and 25 mg of HCT). Six replicate 
determinations were carried out and experimental values are 
presented in table 3. The percentage assay result obtained ranged 
from 98-101. Therefore, the proposed method can be successfully 
applied for the quantitative analysis of ALI and HCT in tablet 
formulation. 
 
Table 3: Analysis of formulation 
Drugs Labeled amount (mg/tablet) Amount found (%)* % RSD* 
ALI 300 100.36±0.9201 0.9097 




The validated RP-HPLC method employed here proved to be simple, 
fast, accurate, precise, cost effective and highly sensitive as 
compared to existing methods. The method uses simple reagents 
and sample preparation procedures were minimal. Therefore, the 
proposed method can be used successfully for routine analysis of 
ALI and HCT in tablet dosage form without any interference from 
the excipients used in the tablet formulation. 
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